Beroni Group
Sydney, Australia· Est.
Australian‑listed biotech developing cell therapies, anti‑cancer drugs and diagnostics across Asia and the US.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $12M
AI Company Overview
Australian‑listed biotech developing cell therapies, anti‑cancer drugs and diagnostics across Asia and the US.
OncologyInfectious DiseasesRegenerative Medicine
Technology Platform
Immune‑cell engineering combined with mitochondrial ANT inhibition (PENAO) and colloidal‑gold immunoassay diagnostics.
Opportunities
Scaling its e‑commerce platform to distribute emerging therapeutics across Asia and leveraging PENAO’s novel mechanism for oncology partnerships.
Risk Factors
Early‑stage pipeline with no clinical data, regulatory hurdles, and reliance on external financing for development.
Competitive Landscape
Competes with established cell‑therapy firms (e.g., Novartis, Gilead) and oncology drug developers; differentiation lies in its mitochondrial ANT inhibitor and integrated e‑commerce distribution.